CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
25.16
+1.42 (5.98%)
At close: May 12, 2025, 4:00 PM
25.16
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
CG Oncology Revenue
In the year 2024, CG Oncology had annual revenue of $1.14M with 458.33% growth. CG Oncology had revenue of $456.00K in the quarter ending December 31, 2024, with 45,500.00% growth.
Revenue (ttm)
$1.14M
Revenue Growth
+461.08%
P/S Ratio
1,683.71
Revenue / Employee
$10,080
Employees
113
Market Cap
1.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.14M | 935.00K | 458.33% |
| Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
| Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
| Dec 31, 2021 | 10.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 14 days ago - CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why - Benzinga
- 16 days ago - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - GlobeNewsWire
- 5 weeks ago - CG Oncology Looks Attractive At Current Prices (Rating Upgrade) - Seeking Alpha
- 7 weeks ago - Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy - GlobeNewsWire
- 2 months ago - CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 5 months ago - CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 months ago - CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene - Seeking Alpha
- 5 months ago - CG Oncology Announces Pricing of Public Offering - GlobeNewsWire